Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Phase 1/2 Terminated
52 enrolled 31 charts
PIKHER2
Phase 1/2 Terminated
24 enrolled
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Phase 1/2 Terminated
50 enrolled
TAKTIC
Phase 1/2 Terminated
68 enrolled
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
Phase 1/2 Terminated
2 enrolled 15 charts
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 1/2 Terminated
2 enrolled
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Terminated
110 enrolled
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Phase 1/2 Terminated
214 enrolled
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
23 enrolled
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
23 enrolled
TRI-LARC
Phase 1/2 Terminated
94 enrolled
INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer
Phase 1/2 Terminated
6 enrolled
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
188 enrolled
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Phase 1/2 Terminated
179 enrolled
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
Phase 1/2 Terminated
73 enrolled
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
Phase 1/2 Terminated
19 enrolled
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Terminated
16 enrolled
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Phase 1/2 Terminated
5 enrolled
CMP-001 for Relapsed and Refractory Lymphoma
Phase 1/2 Terminated
14 enrolled 11 charts
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1/2 Terminated
13 enrolled
EV-103
Phase 1/2 Terminated
348 enrolled 2 FDA
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Phase 1/2 Terminated
63 enrolled 33 charts
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Phase 1/2 Terminated
19 enrolled 11 charts
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Phase 1/2 Terminated
20 enrolled 34 charts
NK4AML
Phase 1/2 Terminated
9 enrolled
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Phase 1/2 Terminated
28 enrolled
NEPI
Phase 1/2 Terminated
1 enrolled
CELLO-1
Phase 1/2 Terminated
102 enrolled 39 charts
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Phase 1/2 Terminated
5 enrolled
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Phase 1/2 Terminated
59 enrolled
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase 1/2 Terminated
42 enrolled
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
Phase 1/2 Terminated
13 enrolled
HeartPhone Cancer Survivors Trial 2019
Phase 1/2 Terminated
2 enrolled 6 charts
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1/2 Terminated
8 enrolled 11 charts
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
Phase 1/2 Terminated
8 enrolled
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Phase 1/2 Terminated
53 enrolled 22 charts
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase 1/2 Terminated
13 enrolled
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
Phase 1/2 Terminated
44 enrolled
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Phase 1/2 Terminated
3 enrolled 8 charts
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Phase 1/2 Terminated
25 enrolled 11 charts
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Phase 1/2 Terminated
51 enrolled
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 1/2 Terminated
200 enrolled
TEM-GU
Phase 1/2 Terminated
10 enrolled
SANTANA-225
Phase 1/2 Terminated
2 enrolled
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Phase 1/2 Terminated
46 enrolled 22 charts